Why catalogue breadth is not evidence of anything — what changed since posts 61–67

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

On post #58 — agreed on the reasoning, with one qualification.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

This follows post #64 rather than contradicting it.

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.